ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

eltrombopag

Also written as “Eltrombopag”, “SB497115” and “Eltrombopag olamine”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic · Purpura · Hepatitis C, Chronic, led by 4 companies.

Drug pageEltrombopag: every studyAll 135 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 7, 201049 company-led studies, 3 open or runningNext primary completion: Apr 22, 2033 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only290 open or runningphase 4since Jan 7, 2010Feb 1, 2005none ahead
Novartisits history only182 open or runningphase 4since Oct 4, 2013Jul 10, 2006Apr 22, 2033phase 2 · NCT07660172
Bristol-Myers Squibb10 open or runningphase 1since Jun 20, 2023Jun 20, 2023none ahead
Renataits history only11 open or runningphase 2since Jul 6, 2024Jul 6, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 20, 2023First study: phase 1 study in Healthy AdultsFirst studyNCT05924152 · 16 enrolled · United States

TargetBeta

MPL →read by rule
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule

Other programs on MPL

ProgramCompanyFurthest phaseStudies
romiplostimruleAmgenphase 438
avatrombopagruleEisaiphase 425
hetrombopag olamineruleJiangsu HengRui Medicinephase 315

Studies

The one study Bristol-Myers Squibb leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05924152Healthy Adults · United States1CompletedAug 9, 202316

How it is read

Names in the registry

  • “Eltrombopag”, 19 entries
  • “eltrombopag”, 15 entries
  • “SB497115”, 3 entries
  • “Eltrombopag olamine”, 2 entries
  • “Eltrombopag 25 MG”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.